Selected article for: "confidence interval and exposure date"

Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018
  • Document date: 2018_10_25
  • ID: 60ceejq1_495
    Snippet: Our findings suggest a higher rate of E. coli resistance to third generation cephalosporins is found in canine patients compared to human pediatric patients. While this difference could be due to differences in Of the feline fecal flotation tests performed, 3,949 (0.13%) were positive for the presence of A. abstrusus larvae. In addition, 65 (2.3%) of the Baermann tests conducted were also positive. As reported in other studies, age was a signific.....
    Document: Our findings suggest a higher rate of E. coli resistance to third generation cephalosporins is found in canine patients compared to human pediatric patients. While this difference could be due to differences in Of the feline fecal flotation tests performed, 3,949 (0.13%) were positive for the presence of A. abstrusus larvae. In addition, 65 (2.3%) of the Baermann tests conducted were also positive. As reported in other studies, age was a significant risk factor with cats 1 to 12 months having a relative risk of 5.72 (95% confidence interval: 5.30-6.18, P < 0.0001) compared to cats older than 12 months. In contrast, there was no association observed between infection status and sex. Significant variation in Overall 5.0%, 6.8%, and 3.9% of sera were ELISA reactive to The results to date suggest that dogs with primary exposure to this dose and strain of H3N2 will be contagious for up to 5 days. The goal of this study was to evaluate the indications, dosing, potential adverse effects, and survival to discharge in dogs and cats treated with vancomycin. An additional goal was to evaluate if vancomycin treatment was based on current recommendations and best practices.

    Search related documents:
    Co phrase search for related documents
    • cat dog and risk factor: 1, 2, 3
    • cat dog and significant variation: 1
    • confidence interval and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • confidence interval and sex infection status: 1, 2, 3
    • confidence interval and significant variation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • current recommendation and risk factor: 1, 2
    • generation cephalosporin and risk factor: 1, 2, 3
    • good practice and risk factor: 1, 2, 3, 4, 5, 6
    • good practice and significant variation: 1, 2, 3
    • high rate and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high rate and sex infection status: 1
    • high rate and significant variation: 1, 2, 3, 4, 5
    • infection status and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • infection status and sex infection status: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • infection status and significant variation: 1, 2
    • Overall significant variation and significant variation: 1, 2, 3
    • pediatric patient and risk factor: 1, 2
    • potential adverse effect and risk factor: 1
    • primary exposure and risk factor: 1, 2, 3, 4, 5